This is precisely why the date is your ultimate authority
How a Genetic Report Changes Dosing A pharmacogenomic test that includes CYP2D6, CYP3A4, CYP2C19, and NOS3 variants gives you three things a standard dosing guide can't: Metabolizer phenotype: Where you fall on the poor-to-ultrarapid spectrum, so you know whether to start low, go standard, or consider higher doses Drug interaction risk: Whether your current medications compete with BPC-157 for the same metabolic pathways Vascular sensitivity: Whether your NOS3 variants suggest starting with extra caution on the assessment dose This doesn't replace working with a qualified practitioner
Weigh convenience against waste when deciding whether partial reconstitution makes sense for your situation
Two of the most commonly referenced forms are: GHK-Cu (Copper Tripeptide-1) AHK-Cu (Copper Tripeptide-3) While both belong to the copper peptide family, they are used differently in cosmetic formulation depending on whether the goal is skin-focused or scalp- and hair-focused performance
The evidence behind that is mouse data
Use of this peptide for any other reason is at your own risk and is not recommended nor approved by the FDA